Living with a rare genetic neurodevelopmental disorder
August 5, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing KAT6A, feature, patient experience, pharma, rare disease
Vaila Morrison’s daughter Eilidh was born with the ultra-rare condition KAT6A. As a designer and architect by profession, Vaila told …
Additional data for Boehringer’s Giotrif combo shows strong overall survival benefit in lung cancer sub-population
August 5, 2019Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, giotrif, lung cancer, pharma
German firm Boehringer Ingelheim has released new interim data from a real-world evidence study investigating the efficacy of Giotrif/Gilotrif (afatinib) …
New model can help predict cognitive decline in patients with Alzheimer’s
August 5, 2019Sales and Marketing Alzheimer's pharma, cognitive decline, computing, dementia, pharma
Scientists at MIT have developed a new model which can predict whether patients at risk for Alzheimer’s disease will experience …
Pollen spores could be used to protect potent, ocean-dwelling antibiotics in fighting antibiotic resistant superbugs
August 5, 2019Research and Development, Sales and Marketing AMR, Antibiotics, MRSA, club moss, pharma, pollen, spores
Spores from a plant called the common club moss (Lycopodium clavatum) could be used to protect light-sensitive antibiotics, that are …
Daiichi Sankyo’s Turalio becomes first FDA-approved therapy for rare tumour
August 5, 2019Sales and Marketing Cancer, Daiichi Sankyo, FDA, Turalio, US, pharma, rare cancer
Daiichi Sankyo has seen its CSF1R inhibitor Turalio (pexidartinib) approved by the FDA in the treatment of symptomatic tenosynovial giant …
Roche’s Tecentriq meets primary endpoint in Phase 3 bladder cancer trial
August 5, 2019Sales and Marketing Cancer, Roche, bladder cancer, immunotherapy, oncology, tecentriq
Roche has said its immunotherapy drug Tecentriq (Atezolizumab), when used in combination with platinum-based chemotherapy, significantly reduced the risk of …
Top UK doctors warn Boris Johnson that no-deal Brexit would cause key cancer therapy supply shortages
August 2, 2019Manufacturing and Production, Medical Communications Cancer, NHS, UK, brexit, pharma
Top doctors from some of the UK’s foremost nuclear medicine associations have written a letter to recently-anointed Prime Minister Boris …
Dr Wajid Hussain appointed new clinical director for digital health at RCP
August 2, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing IT, RCP, Royal College of Physicians, digital health, pharma
The Royal College of Physicians (RCP) has appointed Dr Wajid Hussain as its new clinical director for digital health. Dr …
Top Ten most popular articles on Pharmafile.com this week!
August 2, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Pfizer dominated the headlines this week as the US firm closed its $9.8 billion merger with GSK and announced that …
AI accurately detects subtle signs of atrial fibrillation even in normal tests
August 2, 2019Medical Communications AF, AI, ECG, atrial fibrillation, electrcardiogram, pharma
A new study from the Mayo Clinic shows that artificial intelligence (AI) can detect signs of atrial fibrillation (AF) in …
European approval for two new delivery formulations of GSK’s Nucala in severe eosinophilic asthma
August 2, 2019Medical Communications, Sales and Marketing Europe, GSK, Nucala, asthma, pharma
Following closely on the heels of the news that its deal to merge Pfizer’s consumer health business with its own, …
US presidential candidate Bernie Sanders pledges to allow Americans to import drugs from Canada
August 2, 2019Medical Communications Bernie Sanders, Canada, Trump, US, democrats, prescription drugs
Democratic presidential candidate Bernie Sanders has said he will, on his first day in office, allow for the importation of …
Janssen returns rights for experimental cancer immunotherapy to Alligator Bioscience, sending shares spiraling by 40%
August 1, 2019Sales and Marketing Alligator Bioscience, Janssen, pahrma
Janssen has decided to hand back the rights to an experimental CD40 agonistic antibody to Alligator Bioscience as it reassesses …
Novartis’ Kisqali reinforces overall survival benefit in postmenopausal HR+/HER2- breast cancer
August 1, 2019Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma
New Phase 3 evidence has emerged on the efficacy of Novartis’ Kisqali (ribociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) in …
GSK closes the deal with Pfizer over $9.8 billion consumer healthcare merger
August 1, 2019Sales and Marketing GSK, Pfizer, merger, pharma
The $9.8 billion joint venture between major pharma firms GlaxoSmithKline and Pfizer to merge their consumer health operations has come …
Bayer’s Xarelto combo greenlighted by NICE for reducing CV events in artery disease
August 1, 2019Sales and Marketing NHS, NICE, UK, Xarelto, cardiovascular disease, pharma
NICE has awarded final appraisal recommendation to Bayer’s Xarelto (rivaroxaban) at a dosage of 2.5mg twice daily in combination with …
FDA steps up 2018 drug approvals by 11% on previous year
August 1, 2019Sales and Marketing EMA, FDA, drug approvals, pharma
The FDA continues to excel in the ground it covers as it emerges that the total number of new drug …
MSD to bring over 400 new jobs to North Carolina with two site expansions
July 31, 2019Manufacturing and Production, Research and Development MSD, US, pharma
MSD has announced a $650 million expansion of its existing facilities in North Carolina – a move which is bring …
Biogen & Alkermes’ multiple sclerosis drug proves “statistically superior” to Tecfidera at Phase 3
July 31, 2019Research and Development Alkermes, Biogen, multiple sclerosis, pharma
Biogen and Alkermes have unveiled new Phase 3 data for diroximel fumarate, comparing the adequacy of the therapy to Biogen’s …
Lilly’s Verzenio combo shows additional breast cancer survival benefit in new Phase 3 data
July 31, 2019Research and Development Cancer, Eli Lilly, Verzenio, breast cancer, pharma
Eli Lilly has revealed new Phase 3 data on its CDK4 & 6 inhibitor Verzenio (abemaciclib), demonstrating its efficacy in …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
